Live Longer with KISQALI

Overall Survival Results

Living Longer is Possible and Proven With KISQALI

KISQALI® (ribociclib) is approved for both pre- and postmenopausal women with HR+, HER2- metastatic breast cancer (mBC). KISQALI has extended lives in multiple clinical trials when taken in combination with a nonsteroidal aromatase inhibitor or fulvestrant. Watch the video below to find out what it means to be a Thriver with mBC and why women are asking for KISQALI by name. 

 

See Premenopausal Results > | See Postmenopausal Results >

Mbc Thrivers

Results for Premenopausal Women Taking KISQALI + a Nonsteroidal Aromatase Inhibitor + Goserelin

KISQALI was studied in a clinical trial dedicated exclusively to younger women. The median age was 44 years (range 25 to 58). 495 women were treated with KISQALI + a nonsteroidal aromatase inhibitor (NSAI) (ie letrozole or anastrozole) + goserelin or an NSAI + goserelin.

KISQALI®(ribociclib) Estimated Survival Rates

Overall survival

In a clinical trial, KISQALI + an NSAI + goserelin extended the length of time women were alive from the start of treatment—also called overall survival (OS). Median OS is the length of time when half of the women were still alive. At a 54-month observational check in, results showed the median overall survival (OS) was 58.7 months for KISQALI + NSAI + goserelin vs 47.7 months for NSAI + goserelin. This 54 month analysis was not pre-planned to detect a false positive or show a difference between treatments. 

Progression-Free Survival with KISQALI® (ribociclib) + an NSAI + goserelin

Median progression-free survival

In the same clinical trial, half the women taking KISQALI + an NSAI + goserelin still showed no disease progression after 27.5 months vs 13.8 months for women taking an NSAI + goserelin. Median progression-free survival (PFS) is the length of time when half of the women had not yet progressed.

Response rates for women taking KISQALI® (ribociclib) + an NSAI + goserelin

Proven to shrink tumors

KISQALI + an NSAI + goserelin worked together to shrink tumors in women who had measurable tumors.

 

Results for Postmenopausal Women Taking KISQALI + Fulvestrant

In a clinical trial with 726 women, 484 were treated with KISQALI + fulvestrant and 242 women were treated with fulvestrant alone.

Estimated Survival Rates for postmenopausal women taking KISQALI® (ribociclib) + fulvestrant

Overall survival

In a clinical trial, KISQALI + fulvestrant extended the length of time women were alive from the start of treatment—also called overall survival (OS). Median OS is the length of time when half of the women were still alive. Median OS was not reached for KISQALI + fulvestrant (meaning more than half of the women were still alive at the time of the analysis) vs a median of 40 months for those taking fulvestrant alone.

 

 

Postmenopausal progression free-survival while taking KISQALI® (ribociclib) + fulvestrant

Median progression-free survival

In the same clinical trial, half the women taking KISQALI + fulvestrant still showed no disease progression after 20.5 months vs 12.8 months for women taking fulvestrant alone. Median progression-free survival (PFS) is the length of time when half of the women had not yet progressed.

Response rates for postmenopausal women taking KISQALI® (ribociclib) + fulvestrant

Proven to shrink tumors

KISQALI + fulvestrant worked together to shrink tumors in women who had measurable tumors.